Bash Alan reported grant involving 4,908 shares of Legend Biotech Corp at $0.00 for $0 on Aug 14, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Interim CEO
Interim CEO
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
4,908Ordinary Shares
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
35,142Direct
Trade date
Aug 14, 2026Grant
Filed
Aug 18, 2026, 4:15 PM ET4-day reporting delay
Accession
0001908421-26-000005Code A · Transaction 2181
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LEGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LEGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.1%1w ago −5.3%1d ago −7.5%
Returns since7d −1.6%30d −20%90d180d1y

Footnotes in full

F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2: Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of July 27, 2027, July 27, 2028, and July 27, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.